Results
ARDS identified.‡The, ARDS
DISEASE, ARDS, ACUTE RESPIRATORY DISTRESS SYNDROME
Of the 412 patients enrolled into the REST trial, 1-year mortality status was available for 401 patients (198 (49.4%) randomised to receive intervention and 203 (50.6%) randomised to receive standard care), and 2-year mortality status was available for 391 patients (194 intervention, 197 standard care). Of patients alive at 1 year, 161 provided at least one questionnaire response (
Baseline characteristics of all patients who responded to at least one questionnaire 1 year following randomisationBaseline clinical data were collected in the 24 hours prior to randomisation unless stated otherwise. If more than one value was available for this 24-hour period, the value closest but prior to the time of randomisation was recorded.Data presented as median (IQR) unless otherwise stated. Where median (IQR) presented, p value is from a Wilcoxon rank sum. Where, N (%) presented, p value is from a χ*The predicted body weight of male patients was calculated as equal to 50+0.91 (centimetres of height—152.4); that of female patients was calculated as equal to 45.5+0.91 (centimetres of height—152.4).†Patients may have had more than one admission diagnostic category or cause of ARDS identified.‡The presence of ARDS was assessed by the treating physician.§Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating greater severity of illness.¶Scores on the Sequential Organ Failure Assessment (SOFA) scale range from 0 to 24, with higher scores indicating greater severity of disease.**Tidal volume represents the pre-randomisation value.††Driving Pressure = Plateau Pressure − PEEP.‡‡Second qualifying PaOAPACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; FiOFlow of patients in the REST trial. After randomisation, patients allocated to intervention had a lower daily tidal volume (to day 7), and a lower PaO